<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>MS-153 ((R)-(-)-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-nicotinoyl-2-pyrazoline) is a novel pyrazoline compound that has potent cerebroprotective effects in the rat focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="1" pm="."><plain>Middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in rats allows detailed assessment of both functional and morphological sequelae of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Using this model, we evaluated the cerebroprotective effects of MS-153 </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with MS-153 (12.5 mg/kg, i.v. bolus followed by 6.25 mg/kg/hr or 25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 7 days) significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes and improved neurological deficits in <z:chebi fb="70" ids="34342">MCA</z:chebi> occluded rats 7 days after occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Delayed treatment significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 24 hr after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 21 hr) administration was started 3 hr after occlusion </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002181'>Brain edema</z:hpo> was also significantly improved when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 18 hr) administration was started 6 hr after occlusion </plain></SENT>
</text></document>